Tasimelteon (BMS-214778) (Synonyms: BMS 214778) |
Catalog No.GC30781 |
Le tasimeltéon (BMS-214778) (BMS-214778) est un agoniste double des récepteurs de la mélatonine (DMRA) actif et sélectif par voie orale.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 609799-22-6
Sample solution is provided at 25 µL, 10mM.
Tasimelteon is a melatonin MT1 and MT2 receptor agonist.Target: melatonin receptorTasimelteon is a novel circadian regulator, is the first product for the treatment of Non-24-hour Sleep-Wake Disorder (Non-24) approved by either the FDA or the European Medicines Agency (EMA). Tasimelteon is a potent and specific melatonin (MT1 and MT2) receptor agonist with 2 - 4 times greater affinity for the MT2 receptor.
[1]. Leger D, et al. Safety profile of tasimelteon, a melatonin MT1 and MT2 receptor agonist: pooled safety analyses from six clinical studies. Expert Opin Drug Saf. 2015;14(11):1673-85. [2]. Keating GM, et al. Tasimelteon: A Review in Non-24-Hour Sleep-Wake Disorder in Totally Blind Individuals. CNS Drugs. 2016 Mar 22.
Average Rating: 5
(Based on Reviews and 17 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *